Synexa Life Sciences is an industry leader in contract bioanalytics and biomarker research services specializing in biopharmaceuticals. It delivers bespoke bioanalytical solutions to meet its global clients’ specific challenges and clinical milestones.

Founded in 2003 as an early pioneer in the biomarker field, Synexa continues to specialize in the development, validation, and delivery of a wide range of complex and custom-designed analytical techniques. Synexa’s clients include leading large pharmaceutical companies, innovative biotech firms, and biosimilar developers in Europe, the US, and Asia. Biomarkers play a vital role in drug development by understanding the effects of novel drugs on humans. Effective use of biomarkers has been identified in studies as a valuable factor driving improvements in clinical productivity and success rates, leading to lower cost of drug development, and increasing the likelihood of regulatory approval.

Gilde Healthcare invested in Synexa in 2019 and has supported the expansion of Synexa’s laboratories, investments in the team, and analytical platforms as well as further M&A growth.